Guided Therapeutics (GTHP) FCF Payout Ratio (2023 - 2024)
Guided Therapeutics recorded quarterly FCF Payout Ratio of 0.26 in Q2 2024, up 60.77% quarter-over-quarter from 0.65 in Q1 2024.
Guided Therapeutics' FCF Payout Ratio history runs 2 years deep, the most recent figure standing at 0.26 for Q2 2024.
- In Q2 2024, FCF Payout Ratio changed N/A year-over-year to 0.26; the TTM figure through Jun 2024 stood at 0.11 (down 209.28% YoY), while the FY2023 annual figure was 0.04, up 52.99% from the prior year.
- FCF Payout Ratio came in at 0.26 for Q2 2024 at Guided Therapeutics, up from 0.65 in the prior quarter.
- In the past five years, FCF Payout Ratio ranged from a high of 0.13 in Q1 2023 to a low of 0.65 in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.20 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 0.81 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.40 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 0.08 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 0.25 |
| 10 | Guided Therapeutics | - | - | 458,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -0.26 |
| Mar 31, 2024 | -0.65 |
| Mar 31, 2023 | -0.13 |